Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Androgenetic Alopecia Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

40 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men 40 to 60 years of age, and in good general physical and mental health, with androgenetic alopecia

Exclusion criteria

History of previous bladder surgery, acute urinary retention, urethral strictures, repeated urethral catheterizations, repeated urinary tract infections, or active urinary tract infections
History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any component of finasteride.

Treatment and study plan

MK0906, finasteride / Duration of Treatment : 48 Weeks

Drug

Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks

Drug

Primary outcomes

Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment

Secondary outcomes

Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia

Important dates

Study start: 1998
Primary completion: 2000
First posted: Nov 6, 2006
Registry last updated: Feb 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed